Versartis, Inc. (NASDAQ:VSAR)‘s stock had its “buy” rating restated by investment analysts at Piper Jaffray Companies in a report released on Friday. They currently have a $26.00 price target on the biopharmaceutical company’s stock. Piper Jaffray Companies’ price objective points to a potential upside of 30.33% from the stock’s previous close.

A number of other equities analysts also recently weighed in on VSAR. BidaskClub downgraded shares of Versartis from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. ValuEngine downgraded shares of Versartis from a “hold” rating to a “sell” rating in a research note on Thursday, August 17th. Zacks Investment Research downgraded shares of Versartis from a “hold” rating to a “sell” rating in a research note on Wednesday, August 2nd. Canaccord Genuity set a $28.00 target price on shares of Versartis and gave the stock a “buy” rating in a research note on Sunday, May 28th. Finally, Cowen and Company reissued an “outperform” rating and set a $45.00 target price on shares of Versartis in a research note on Wednesday, August 23rd. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Versartis has a consensus rating of “Buy” and a consensus target price of $27.88.

Shares of Versartis (NASDAQ VSAR) traded down 4.77% during trading on Friday, hitting $19.95. 416,587 shares of the stock traded hands. The firm has a 50-day moving average of $18.28 and a 200-day moving average of $18.50. The firm’s market capitalization is $709.78 million. Versartis has a 1-year low of $9.05 and a 1-year high of $24.00.

Versartis (NASDAQ:VSAR) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by $0.20. On average, equities analysts forecast that Versartis will post ($3.49) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Versartis, Inc. (VSAR) Rating Reiterated by Piper Jaffray Companies” was published by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/09/08/versartis-inc-vsar-rating-reiterated-by-piper-jaffray-companies.html.

Institutional investors and hedge funds have recently bought and sold shares of the business. First Quadrant L P CA bought a new stake in Versartis in the second quarter valued at $155,000. Bank of America Corp DE increased its stake in Versartis by 46.3% in the first quarter. Bank of America Corp DE now owns 9,482 shares of the biopharmaceutical company’s stock valued at $203,000 after purchasing an additional 3,001 shares in the last quarter. Tudor Investment Corp ET AL bought a new stake in Versartis in the second quarter valued at $218,000. Numeric Investors LLC bought a new stake in Versartis in the second quarter valued at $246,000. Finally, Voya Investment Management LLC increased its stake in Versartis by 26.1% in the second quarter. Voya Investment Management LLC now owns 14,960 shares of the biopharmaceutical company’s stock valued at $261,000 after purchasing an additional 3,094 shares in the last quarter. 78.77% of the stock is owned by hedge funds and other institutional investors.

About Versartis

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Analyst Recommendations for Versartis (NASDAQ:VSAR)

Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.